ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,027,303 | -48.5% | 74,698 | -41.7% | 0.00% | 0.0% |
| Q2 2023 | $3,938,931 | +192.8% | 128,137 | +243.2% | 0.00% | 0.0% |
| Q1 2023 | $1,345,108 | +22.4% | 37,333 | +34.2% | 0.00% | 0.0% |
| Q4 2022 | $1,099,288 | +46.8% | 27,816 | +49.1% | 0.00% | – |
| Q3 2022 | $749,000 | +208.2% | 18,650 | +222.1% | 0.00% | – |
| Q2 2022 | $243,000 | -97.5% | 5,790 | -97.7% | 0.00% | -100.0% |
| Q1 2022 | $9,703,000 | -47.8% | 249,072 | -46.6% | 0.00% | -40.0% |
| Q4 2021 | $18,580,000 | -10.3% | 466,259 | -18.7% | 0.01% | -37.5% |
| Q3 2021 | $20,725,000 | +150.3% | 573,465 | +183.9% | 0.01% | +166.7% |
| Q2 2021 | $8,280,000 | -63.7% | 202,007 | -61.4% | 0.00% | -72.7% |
| Q1 2021 | $22,816,000 | +210.8% | 523,037 | +256.6% | 0.01% | +175.0% |
| Q4 2020 | $7,342,000 | +1201.8% | 146,691 | +994.7% | 0.00% | – |
| Q3 2020 | $564,000 | -72.6% | 13,400 | -68.4% | 0.00% | -100.0% |
| Q2 2020 | $2,060,000 | – | 42,425 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |